Transvaginal Versus Fluoroscopy-guided Trans Gluteal Pudendal Nerve Block for Pudendal Neuralgia
University of Louisville · NCT06644261
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- June 27, 2024
- Record last updated
- December 18, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Chronic pain affecting the pelvic and urogenital area is a major clinical problem and can have a profound impact on quality of life and health care costs. Pelvic pain arising from entrapment or neuropathy of the pudendal nerve is known as pudendal neuralgia, which results in chronic perineal pain. This pain syndrome is difficult to diagnose and patients with pudendal neuralgia may present to providers with refractory chronic pelvic pain. Pudendal nerve infiltration or pudendal nerve block (PNB) serves as a diagnostic tool and treatment modality for patients with this condition. To date, there are no published randomized controlled trials comparing imaging-guided PNB to transvaginal finger-guided PNB. While one can assume that image-guided nerve blocks will provide better accuracy for injection and potentially better efficacy in pain relief as a result, no published data exists comparing the outcomes and efficacy between modalities.
The purpose of this prospective, non-inferiority, randomized controlled trial is to compare the efficacy of pain relief from bilateral transvaginal finger-guided pudendal nerve block versus bilateral fluoroscopy-guided trans gluteal pudendal nerve block for patients with pudendal neuralgia.
Being studied: Bupivacaine injection
Conditions: Pudendal Neuralgia; Chronic Pelvic Pain Syndrome
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- women >18 years
- English speaking/reading
- Diagnosis of pudendal neuralgia OR chronic pelvic pain with pain in the distribution of the pudendal nerve for 3 months or longer
- Minimum pain/bother score of 4/10
- Desire for pudendal nerve block
Exclusion Criteria
- Contraindication to pudendal nerve block (examples: skin or vaginal infection, bupivacaine allergy, uncorrected coagulopathy)
- Pregnant or intending to become pregnant during the study
- Pudendal nerve block from any route within the last 3 months
- Major pelvic surgery within the last 3 months (examples: hysterectomy, prolapse repair, midurethral sling)
- Neurologic disease affecting the perineum (examples: spinal cord injury, multiple sclerosis)
Recruiting US locations
University of Louisville Division of Urogynecology and Reconstructive Pelvic Surgery
Louisville, KY 40202
Site contact: Laurel Carbone, MD · 502-588-7660 · laurel.carbone@louisville.edu
Study contacts (from the official record)
- Laurel Carbone, MD · 502-588-7660 · laurel.carbone@louisville.edu
- Sean Francis, MD · 502-588-7660 · sean.francis@louisville.edu
Similar studies in Kentucky
All healthy volunteers studies in Kentucky →- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- Louisville, KY + 14 other US sites
- Eligibility basics
- Ages 2 mo–1
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Louisville, KY + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Gilead Sciences
- Location
- Louisville, KY + 4 other US sites
- Eligibility basics
- Ages 18–69
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Louisville, KY + 18 other US sites
- Eligibility basics
- Ages 18–100